Similar articles

• Phase II study of hepatic artery infusion with 5-fluorouracil, adriamycin, and mitomycin C (FAM) in liver metastases from colorectal carcinoma.

  Wils J, Schlangen J, Naus A. Wils J, et al. Cancer Chemother Pharmacol. 1984;13(3):215-7. doi: 10.1007/BF00269032. Cancer Chemother Pharmacol. 1984. PMID: 6548420
• [Chemotherapy of gastrointestinal cancer in the advanced stage with a combination of 5-fluorouracil, adriamycin, mitomycin C (FAM). A non-controlled study].

  Grieco A, Lasorella A, Astone A, Vagliviello L, Bartoloni C, Barone C. Grieco A, et al. Clin Ter. 1984 Aug 31;110(4):353-8. Clin Ter. 1984. PMID: 6237871 Italian. No abstract available.
• Hematological toxicity of adjuvant portal liver infusion with fluorouracil, mitomycin and heparin.

  Weber W, Metzger U, Laffer U, Egeli R. Weber W, et al. Anticancer Res. 1991 Jan-Feb;11(1):365-8. Anticancer Res. 1991. PMID: 1902076 Clinical Trial.
• Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver.

  Stagg RJ, Lewis BJ, Friedman MA, Ignoffo RJ, Hohn DC. Stagg RJ, et al. Ann Intern Med. 1984 May;100(5):736-43. doi: 10.7326/0003-4819-100-5-736. Ann Intern Med. 1984. PMID: 6231876 Review.
• [5-Fluorouracil, adriamycin, and mitomycin C (FAM) combination chemotherapy in adenocarcinoma of the parotid gland].

  Inoue K, Horikoshi N, Mukaiyama T, Ogawa M, Kuraishi Y. Inoue K, et al. Gan No Rinsho. 1989 Mar;35(4):481-5. Gan No Rinsho. 1989. PMID: 2654442 Review. Japanese.